Avalon GloboCare Corp (NASDAQ:AVCO) Is Poised for Market Conquest
Avalon's CAR-Ts are ahead of their time due to key advantages over conventional medicines. AVA-101 shuttles enough genes to decimate two oncology targets (CD19 and CD22).
View full press release